Quarterly ResultMay 5, 2026, 04:14 PM
Solventum Q1 Organic Sales +2.1%; Affirms FY26 Guidance
AI Summary
Solventum reported first-quarter 2026 financial results, with reported sales decreasing 3.0% to $2.0 billion, but organic sales increasing 2.1%. The company achieved adjusted diluted EPS of $1.48, a 10.6% increase year-over-year, and affirmed its full-year 2026 organic sales growth and free cash flow guidance, estimating adjusted EPS toward the high end of its existing range. The company also highlighted the opening of a new R&D center and a manufacturing expansion.
Key Highlights
- Q1 2026 reported sales decreased 3.0% to $2.0 billion.
- Q1 2026 organic sales increased 2.1%.
- Q1 2026 adjusted diluted EPS rose 10.6% to $1.48.
- Q1 2026 free cash flow was $(273) million.
- Affirms full-year 2026 organic sales growth guidance of +2.0% to +3.0%.
- Estimates full-year 2026 adjusted EPS toward the high end of $6.40 to $6.60 range.
- Health Information Systems organic sales grew 4.7% to $342 million.
- Advanced Wound Care organic sales grew 2.1% to $497 million.